LNCAP Transfection Reagent (Prostate Carcinoma)

$331.00$2,041.00

Kit Size VolumePriceAdd to Cart
0.5 ml (Catalog #1789)$331.00
1.5 ml (Catalog #1790)$747.00
1.5 ml CRISPR (Catalog #2166)$947.00
8.0 ml (Catalog #7056)$2,041.00
SKU: LNCAP Category:

Description

Product Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).

Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).


Transfection Reagent for LNCaP Cells (Prostate Carcinoma Cells, CRL-1740)

  • A nanoparticle-based liposome formulation
  • Transfection protocols provided for transfection of small proteins, DNA, mRNA, siRNA, shRNA and microRNA
  • Transfection Enhancer and Complex Condenser reagents are included in the kit
  • Produce higher level of recombinant protein expression with minimal disruption of normal cell function
  • Generate physiologically relevant data you can trust
  • Effective for plasmid DNA/siRNA co-transfection
  • Low cytotoxicity
  • Download in vitro LnCAP transfection protocol: [PDF]
  • Download LnCAP CRISPR/Cas9 transfection protocol: [PDF]
  • Download PowerPoint presentation for LnCAP transfection kit: [PPT]
  • Developed and manufactured by Altogen Biosystems

Transfection Efficiency:

Reagent exhibits at least 85% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.

Transfection Protocol and MSDS:

Download Altogen Biosystems LNCaP Transfection Protocol: [PDF]

Download MSDS: [PDF]

LNCaP Cell Line:

Prostate cancer is considered the most frequent malignancy and the third primary cause of cancer-related deaths among men in the United States, according to the American Cancer Society. Black males have 74% higher odds of developing prostate cancer compared to non-Hispanic white men. With the 5-year survival rate of only 29% for patients with advanced stage disease, further preclinical studies for the development of new treatment regimens are necessary. The LNCaP human prostate adenocarcinoma epithelial cell line is established from the supraclavicular lymph node metastasis of a Caucasian male in 1977 and can grow in aggregates or as a single cell. The LNCaP cells grow readily in vitro, form clones, and are resistant to human fibroblast interferon. In addition to being receptive to hormones, the cell line has a high affinity for androgen receptors in the cytosol as well as nuclear fractions of cells. The cell line expresses prostate specific antigen, and estrogen receptors can be seen in the cytosol. The frequency of the tumor development and the time of tumor appearance are significantly different for males and females. Male mice do develop tumors sooner and at the higher frequency than females. Hormonal manipulations demonstrate that incidence of tumor development correlates with the levels of serum androgen. However, the rate of the tumor growth is not dependent on the gender or hormonal status. The LNCaP prostate cancer cell line is widely used in clinical oncology research. It is considered an appropriate host for studying prostate and hormone functions and is extensively used in drug discovery and different types of biomedical applications. Altogen Biosystems offers nanoparticle-based transfection reagent kits for the LNCaP cell line.

TP537157371775784747578474SilentSNPCT
SPINK511005375147503468147503468Nonsense_MutationSNPCT
TRIML1339976374189068456189068456Missense_MutationSNPCT
HHIPL279802371222717002222717002Missense_MutationSNPCT
TMEM4493109373194336413194336413Missense_MutationSNPGA
PRSS552030743781038883810388838SilentSNPCT
A2M2371292626159262615Missense_MutationSNPCT
TEX145615537175667684556676845Missense_MutationSNPCT
PCDH156521737105607717456077174SilentSNPGT
MAP2K1560437156672745166727451Missense_MutationSNPAC
DSC1182337182873944928739449Missense_MutationSNPCT
APC324375112174916112174916Missense_MutationSNPGA
CCDC405503637177806916578069165Missense_MutationSNPGA

Data:

LNCAP Transfection Reagent

Figure 1. SiRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into LNCaP cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=3).

LNCAP-cells-transfection-protocol

Figure 2. Protein expression of Lamin A in LNCAP cells. DNA plasmid expressing Lamin A or siRNA targeting Lamin A were transfected into LNCAP cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.

Selected citations for LNCAP transfection reagent used in the following publications:

  • PLoS One. 2011 6(1) Identification of distinctive patterns of USP19-mediated growth regulation in normal and malignant cells. Lu Y, Bedard N, Chevalier S, Wing S [PDF]
  • RNA. 2010 16(11):2108-19. RNase L releases a small RNA from HCV RNA that refolds … Malathi et al [PDF]

Selected in vivo transfection product citations (ALTOGEN® IN VIVO Transfection Kits used in the following publications):

  • Nature 2008 454(7203):523-7. Innate immunity induced by composition-dependent RIG-I …Saito et al [PDF]
  • Hypertension. 2014 63(2):353-61. Tissue transglutaminase contributes to … Liu et al [PDF]
  • Circulation Research. 2010 15;107(8). Kruppel-like factor-4 transcriptionally regulates … Cowan et al [PDF]
  • Hypertension. 2012 59(1):158-66. Role of uncoupled endothelial nitric oxide synthase … Gao et al [PDF]
  • Jounal of Biological Chemistry. 2012 287(4):2907. Chaperoning of mutant p53 protein … Gogna et al [PDF]
  • J Proteome Res. 2012(11) Retinal proteome analysis in a mouse model of oxygen-induced … Kim et al [PDF]
  • Gastroenterology. 2011 141(2) Differential type I interferon-mediated autophagic trafficking … Desai et al [PDF]
  • PLoS Pathog. 2014 10(10) Exosomes from hepatitis C infected patients transmit HCV … Bukong et al [PDF]

Altogen Biosystems:
Altogen Biosystems is a life sciences company that manufactures over 100 cell type specific and optimized transfection kits, electroporation buffers, and targeted in vivo delivery kits and reagents. Advanced formulation of reagents and optimized transfection protocols provide highly efficient cellular delivery of biomolecules (proteins, DNA, mRNA, shRNA and siRNA, and small molecule compounds). Read more about transfection technology at Altogen’s Transfection Resource.

Altogen Laboratory Contract Research Services:

Altogen Labs provides good laboratory practice (GLP) compliant preclinical research services for IND applications and drug development. Our biology CRO services includes both efficacy studies (over 90 in-house validated xenograft models) and safety pharmacology/toxicology studies (for more details please visit AltogenLabs.com).

Volume Options:

  • 0.5 ml (Catalog #1789)
  • 1.5 ml (Catalog #1790)
  • 1.5 ml CRISPR (Catalog #2166)
  • 8.0 ml (Catalog #7056)

Additional information

Weight1 lbs
Kit Size (Volume)

0.5 ml (Catalog #1789), 1.5 ml (Catalog #1790), 1.5 ml CRISPR (Catalog #2166), 8.0 ml (Catalog #7056)